MannKind Corp. (MNKD)

[Denise Chanterelle]

Investor Place putting out a trash attack on MNKD. Maybe they should learn to use proper English before publishing. http://investorplace.com/2015/10/biotech-stocks-3/#.VilWG2D46GE

Here's the article:
Mannkind (MNKD) is among major development-stage biotech stocks focused on diabetes therapies. On Oct. 20, it jumped up to its 50-day average (red line), then pulled all the way back to flat. That’s very negative action, particularly for a stock that is already way down on its luck. Let’s see if we can help run salt in the wound.

To play this, buy the MNKD Nov. 20th $3.50 puts (MNKD 151120P00003500) at $0.58 or less. When filled, set up to sell your position at the final target of $0.80 limit, good till canceled. Set a stop at $0.40, good after 10 a.m. ET only.